康诺亚生物医药科技(成都)有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum 2025-08-27 14:02
Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine 2025-06-13 17:02
Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Solid Tumors 2025-04-25 17:44
Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Gastrointestinal Cancers 2025-04-25 11:37
The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine 2025-04-06 10:12
Keymed Biosciences Announces Annual Results of 2024 2025-03-26 23:09
Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis 2025-02-08 09:14
Keymed Biosciences Announces Approval Of Stapokibart For The Treatment Of Chronic Rhinosinusitis With Nasal Polyposis 2024-12-23 22:31
Stapokibart Was Granted Marketing Approval From National Medical Products Administration For The Treatment Of Moderate-to-severe Atopic Dermatitis in Adults 2024-09-13 00:07
Keymed Biosciences Announces Interim Results for First Half of 2024 2024-08-27 21:10
Keymed Biosciences Announces Safety and Efficacy Results of CM313 for Primary Immune Thrombocytopenia Published in NEJM 2024-06-20 14:51
Keymed Biosciences Announces Long-term Efficacy and Safety Data from a Phase III Clinical Trial of Stapokibart for the Treatment of Moderate-to-severe Atopic Dermatitis 2024-06-03 09:14
Keymed Biosciences Announces 2023 Annual Results and Business Updates 2024-03-27 01:16
Keymed Biosciences Announces 2022 Annual Results: Efficiently Promotes Clinical Progress & Proactively Develops Global Strategic Collaboration 2023-03-18 08:00
Keymed and Lepu Biopharma Jointly Announce Global Exclusive Licence Agreement with AstraZeneca for CMG901 2023-02-23 13:01
Keymed Biosciences | The Latest Results from the Phase Ia Clinical Study of CMG901 was presented at the 2023 ASCO GI CANCERS SYMPOSIUM 2023-01-18 09:52
China CDE Grants CMG901 Breakthrough Therapy Designation for Claudin 18.2-Positive Advanced Gastric & Gastroesophageal Junction Cancer 2022-09-22 13:05
Keymed Biosciences Announces Dosing of First Patient in Phase I Trial of Bispecific Antibody CM350 2022-06-10 18:42
FDA granted CMG901 Fast Track Designation for unresectable or metastatic gastric and gastroesophageal junction cancer which have relapsed and/or are refractory to approved therapies 2022-04-20 10:27
CMG901 for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma was granted the Orphan-drug Designation by the Food and Drug Administration of the United States 2022-04-12 15:45
1 2